Prostate-specific antigen-all that rises is not refractory.
After the initiation of androgen suppression in men with prostate cancer, the serum prostate-specific antigen (PSA) level generally declines. A subsequent PSA rise during that suppression usually reflects the presence of a significant component of hormonally refractory prostate cancer. We report a patient with a rising PSA level and elevated testosterone level after depot leuprolide in whom the PSA level subsequently declined with administration of bicalutamide.
Hintz
B L
BL
Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, California, USA.
Van Nieuwenhuize
A
A
Kagan
A R
AR
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000813:Anilides / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D006801:Humans; D007273:Injections, Intramuscular; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009570:Nitriles; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D014105:Tosyl Compounds; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D009570:Nitriles; D014105:Tosyl Compounds; D013739:Testosterone; C053541:bicalutamide; D017430:Prostate-Specific Antigen; D016729:Leuprolide